Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
NCT04706936Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2021
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CBG002 in multiple myeloma (MM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Rate of grade 3 or 4 treatment related adverse effect at 24 weeks and Overall Response Rate at 2 years. Status: unknown.
02
Drugs
CBG002
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04706936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706936.